Cargando…

Relation between high serum hepcidin-25 level and subclinical atherosclerosis and cardiovascular mortality in hemodialysis patients

OBJECTIVE: In hemodialysis (HD) patients, cardiovascular disease (CVD) is the major cause of mortality and morbidity. In atherosclerotic diseases, iron gets accumulated in the arterial wall. Hepcidin is an important hormone in iron metabolism. Furthermore, hepcidin is associated with atherosclerotic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yayar, Özlem, Eser, Barış, Kılıç, Harun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2018
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864805/ https://www.ncbi.nlm.nih.gov/pubmed/29339674 http://dx.doi.org/10.14744/AnatolJCardiol.2017.8019

Ejemplares similares

Serum Hepcidin-25 and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis
por: Zou, Lu-Xi, et al.
Publicado: (2021)

Serum Hepcidin Predicts Uremic Accelerated Atherosclerosis in Chronic Hemodialysis Patients with Diabetic Nephropathy
por: Li, Han, et al.
Publicado: (2015)

Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes
por: Xiao, Yang, et al.
Publicado: (2015)

Serum Hepcidin-25 and Risk of Mortality in Patients on Peritoneal Dialysis
por: Zhong, Zhong, et al.
Publicado: (2021)

Association of Childhood Oral Infections With Cardiovascular Risk Factors and Subclinical Atherosclerosis in Adulthood
por: Pussinen, Pirkko J., et al.
Publicado: (2019)

Serum gamma-glutamyltransferase is not associated with subclinical atherosclerosis in patients with type 2 diabetes
por: Yoon, Hye Eun, et al.
Publicado: (2016)

The association between serum 25-hydroxyvitamin D level and subclinical atherosclerosis in healthy population
por: Mohammadzadeh, Vida, et al.
Publicado: (2020)

Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease
por: Palanca, Ana, et al.
Publicado: (2019)

Serum sclerostin level and its relation to subclinical atherosclerosis in the polycystic ovary syndrome phenotypes: A prospective controlled study
por: İncesu Çintesun, Feyza Nur, et al.
Publicado: (2021)

Serum Endocan Levels and Subclinical Atherosclerosis in Behçet’s Syndrome
por: Nassef, Eman Mostafa, et al.
Publicado: (2022)

Chemerin is not associated with subclinical atherosclerosis markers in prediabetes and diabetes
por: Aydın, Kadriye, et al.
Publicado: (2016)

The relationship between asymptomatic atherosclerosis and hepcidin-25 in chronic kidney disease patients
por: Mohamed, Osama Nady, et al.
Publicado: (2023)

Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma
por: Kamai, Takao, et al.
Publicado: (2009)

Normal-weight obesity is associated with increased risk of subclinical atherosclerosis
por: Kim, Sohee, et al.
Publicado: (2015)

Plasma metabolomic profiling in subclinical atherosclerosis: the Diabetes Heart Study
por: Chevli, Parag Anilkumar, et al.
Publicado: (2021)

Kinetics of serum hepcidin and interleukin-6 levels following COVID-19 infection in hemodialysis patients
por: Touzot, Maxime, et al.
Publicado: (2021)

Cardiovascular risk and testosterone – from subclinical atherosclerosis to lipoprotein function to heart failure
por: Gencer, Baris, et al.
Publicado: (2021)

Differential impact of metabolic syndrome on subclinical atherosclerosis according to the presence of diabetes
por: Won, Ki-Bum, et al.
Publicado: (2013)

Associations Between Life-Course Lipid Trajectories and Subclinical Atherosclerosis in Midlife
por: Yan, Yinkun, et al.
Publicado: (2022)

Serum Retinol but Not 25(OH)D Status Is Associated With Serum Hepcidin Levels in Older Mexican Adults
por: De la Cruz-Góngora, Vanessa, et al.
Publicado: (2019)

Serum hepcidin levels in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Clinical interpretation of serum hepcidin-25 in inflammation and renal dysfunction
por: Chen, Michael X., et al.
Publicado: (2022)

Noninvasive indicators of atherosclerosis in subclinical hypothyroidism
por: Kilic, Ismail Dogu, et al.
Publicado: (2013)

Serum irisin and apelin levels and markers of atherosclerosis in patients with subclinical hypothyroidism
por: Yasar, Hamiyet Yilmaz, et al.
Publicado: (2019)

Glycemic variability is associated with subclinical atherosclerosis in Chinese type 2 diabetic patients
por: Mo, Yifei, et al.
Publicado: (2013)

Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis
por: Sonawane, Kalyani, et al.
Publicado: (2020)

Early Pregnancy Cardiovascular Health and Subclinical Atherosclerosis
por: Benschop, Laura, et al.
Publicado: (2019)

Visceral adiposity index and risks of cardiovascular events and mortality in prevalent hemodialysis patients
por: Chen, Hung-Yuan, et al.
Publicado: (2014)

MMP-1 serum levels predict coronary atherosclerosis in humans
por: Lehrke, Michael, et al.
Publicado: (2009)

Variability of Serum Phosphate in Incident Hemodialysis Patients: Association with All-Cause Mortality
por: ter Meulen, Karlien J., et al.
Publicado: (2023)

Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes
por: Carbonell, Marc, et al.
Publicado: (2018)

Corrigendum to Serum hepcidin levels in multiple sclerosis
Publicado: (2020)

Hemodiafiltration Improves Plasma 25-Hepcidin Levels: A Prospective, Randomized, Blinded, Cross-Over Study Comparing Hemodialysis and Hemodiafiltration
por: Stefánsson, Bergur V., et al.
Publicado: (2012)

Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease
por: Oğuz, Didem, et al.
Publicado: (2016)

Triglyceride-mediated influence of serum angiopoietin-like protein 8 on subclinical atherosclerosis in type 2 diabetic patients: results from the GDMD study in China
por: Zheng, Tianpeng, et al.
Publicado: (2018)

Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating Agents
por: van der Weerd, Neelke C., et al.
Publicado: (2012)

Hepcidin-25, Mean Corpuscular Volume, and Ferritin as Predictors of Response to Oral Iron Supplementation in Hemodialysis Patients
por: Takasawa, Kazuya, et al.
Publicado: (2014)

The relationship between anemia, liver disease, and hepcidin levels in hemodialysis patients with hepatitis
por: Zumrutdal, A., et al.
Publicado: (2012)

The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis
por: Pelusi, Serena, et al.
Publicado: (2013)

Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function
por: Collado, Sílvia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7aof89n4mu10ijlolod5t0eatc